TTTY19

Across TCGA pan-cancer cohorts, TTTY19 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated TTTY19 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TTTY19 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TTTY19 expression acts as an unfavorable survival marker, although some lineages such as ESCA and STAD show a favorable association.

LIHC, BLCA, and ACC are the cancer types where TTTY19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.105	0.786	<.001	72	view →
BLCA	DFS	Tertile	All	0.224	0.627	.027	36	view →
ACC	DFS	Tertile	II,III,IV	0.226	0.725	.009	18	view →
ESCA	OS	Tertile	III,IV	1.000	0.375	.044	12	view →
GBM	DFS	Tertile	All	0.102	0.247	.048	9	view →
STAD	OS	Tertile	II,III,IV	0.875	0.637	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TTTY19–LIHC (OS)

Open the LIHC breakdown →